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Introduction {#sec1}
============

Extracellular vesicles (EVs) were identified in 1983 ([@bib9], [@bib20], [@bib21]). The authors have shown that culture of immature red blood cells---reticulocytes---labeled transferrin receptors were internalized within the reticulocytes and then were repackaged into small (∼50-nm) vesicles and secreted out of the maturing blood reticulocytes into the extracellular space. The name of these vesicles "exosomes" was given by Johnstone et al. ([@bib14]). Exosomes belong to a large family of membrane vesicles referred to as EVs, which generally include microvesicles (100--350 nm), apoptotic blebs (500--1,000 nm), and exosomes (30--150 nm) ([@bib12], [@bib13]). The EVs are involved in many biological processes as intercellular communication messengers ([@bib12], [@bib13]). Their pathophysiological roles have been characterized by various diseases including cancer ([@bib23], [@bib24], [@bib30], [@bib5], [@bib22]). Recently, EVs and especially exosomes have been used as therapeutic targets ([@bib10], [@bib11], [@bib15], [@bib28], [@bib30]) or nanotherapeutic agents ([@bib19]).

Ultracentrifugation is the most common approach for EVs isolation ([@bib27], [@bib16], [@bib18]). Recently, size exclusion chromatography has been introduced after ultracentrifugation ([@bib1]) and other separation techniques have been tested, including OptiPrep density-based separation or immune affinity capture using anti-EpCAM-coated magnetic beads ([@bib26]).Validation of EVs isolation is often based on fluorescent microscopy, scanning electron microscopy, and nanoparticle tracking analysis (NanoSight) ([@bib19]). Under an electron microscope, exosomes show characteristic cup-shaped morphology, appearing as flattened spheres with diameters ranging from 30 to 150 nm ([@bib19]). To identify the proteins, present at the surface of EVs and the ones within EVs, we performed a proteomic approach after Trypsin/Lys C treatment and Amicon filtration. Using this procedure, we were able to identify plasmatic membranes as well as luminal proteins.

At the same time, we were interested in looking for ghost proteins present in and on the surface of vesicles. Ghost proteins or alternative proteins (AltProts) represent the invisible part of the proteome, because they are not currently identified, annotated or added to the current database using bottom-up proteomics ([@bib6]). In fact, mass spectrometric (MS) proteomic strategies are based on protein identification against databases of annotated proteins. However, it has been shown that a large number of proteins have not yet been referenced to these databases, in particular because of the rules used to predict the proteins. Thus, AltProts represent proteins of lower molecular weight than reference proteins (RefProts) and are derived from regions of the RNA described as non-coding. AltProts can be translated from 5′ UTR or 3′ UTR or even by shifting on the open reading frame by +2 or +3. Proteins from these regions do not share common sequences with the RefProts produced from the same mRNA and are therefore not isoforms. Some of these AltProts are also described as encoded by non-coding (ncRNA) and long non-coding RNA. Although the role of these proteins remains largely unexplored, some studies have shown their roles in crucial cell processes ([@bib6], [@bib2], [@bib3]), but as of today they have not been studied in vesicles.

Results {#sec2}
=======

Rat C6 Glioma EVs Purification {#sec2.1}
------------------------------

We previously published a protocol based on the ultracentrifugation approach for EVs isolation from microglia cells ([@bib19]). Here, we present an updated version of this strategy by including an enzymatic digestion step using Trypsin/Lys C for 6 h validated by shotgun proteomics analysis. We thus performed such an approach on vesicles derived from rat C6 glioma cells. Therefore, for C6 glioma EVs isolation, multiple centrifugation steps were used to eliminate debris and other macrovesicles, with the final ultracentrifugation steps to collect EVs pellet. Once EVs were isolated, we have continued their purification by treatment with Trypsin/Lys C. For non-treated EVs (T-0h), the enzyme activity was stopped immediately after its introduction in the tube, so it was considered as a control group compared with EVs incubated for 6 h with enzymes (T-6h) ([Figure 1](#fig1){ref-type="fig"}). After enzymatic treatment, the EVs were controlled by nanoparticle tracking analysis ([Figure S1](#mmc1){ref-type="supplementary-material"}) and then subjected to an Amicon filtration step to separate EVs from the digested peptides coming from protein aggregates and the external part of EVs membrane proteins. The next step was to extract EVs proteins using radioimmunoprecipitation assay buffer (RIPA) buffer, and by filter aided sample preparation (FASP), the proteins were digested and prepared for tandem MS (MS/MS) analyses ([Figure 2](#fig2){ref-type="fig"}).Figure 1Scheme of Trypsin/LysC Digestion on EVsThe trypsin enzyme cleaves peptide chains at the amino acid residues lysine or arginine, except when either is followed by proline, and lysine-C can cleave lysine followed by proline. After 6 h of Trypsin/Lys C treatment, the exterior parts of exosomes membrane proteins are cleaved as well as protein aggregates in the pellet.Figure 2Scheme of EVs Treatment with Trypsin/LysCAfter ultracentrifugation at 100,000 × *g* for 70 min, the EVs were incubated for 6 h with 0.2 μg/mL of Trypsin/Lys C (T-6h) or the enzyme activity was immediately stopped (T-0h). Then the vesicles were filtered through Amicon filter 10 kDa, peptides digested by trypsin were recovered in collection tube, and the treated EVs remained on the filter. The filter was transferred into a new tube, proteins were extracted from EVs, and FASP (trypsin digestion) was performed overnight. In the end all the peptides were analyzed by MS/MS.

Two groups of proteins were identified, one corresponding to EVs membrane proteins (external fragment) and protein aggregates and the other corresponding to EVs membrane proteins (internal fragment) and internal EVs proteins ([Figure 1](#fig1){ref-type="fig"}). Using this procedure, we can purify EVs released from cells in the cell culture medium and can enrich the list of EVs proteins identified by shotgun proteomics ([Data S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, [S3](#mmc4){ref-type="supplementary-material"}, and [S4](#mmc5){ref-type="supplementary-material"}).

Identification of Glioma C6 EVs Proteins by Shotgun Proteomics {#sec2.2}
--------------------------------------------------------------

A total of 115 proteins have been identified from all EVs released by glioma C6 cells ([Table S1](#mmc1){ref-type="supplementary-material"}). String analysis revealed the presence of two major pathways; the first one is centered on Fn1 and includes, e.g., TGFα1, Notch1, Notch2, Adam10, Syndecan-1, and Syndecan-2, and the second is centered on CD63 and included, e.g., CD81, CD14, CD9, and annexins. Both pathways are connected by CD44, CD9, and RhoA proteins ([Figure S2](#mmc1){ref-type="supplementary-material"}A). All these proteins are known to be implicated in tumorigenesis, therefore the EVs carry a cell-type-specific signature ([@bib17]). KEGGS analyses revealed 11 proteins involved in cancer (CD44, CD63, RhoA, Socd3,Sdc1, Itgb1, Fn1, Tgfb1,Vcam, Rras, Rac1) and 14 in glioblastoma (CD44, FnA, Itgb1, Tgfb1,ECm1,App, Anxa1, HSP90aa1,Flot1, HSP90ab1,Rab7a, Pdcd6ip, Dnja2, Mvp). From the 115 identified proteins, whatever the fractions (internal or external), 15 proteins are unique to EVs not treated with Trypsin/Lys C (T-0h) and 100 proteins are specific to EVs treated for 6 h (T-6h) ([Figure S2](#mmc1){ref-type="supplementary-material"}B).

Among the 15 proteins identified from non-treated EVs, a pathway including GABA(A) receptor-associated protein-like 1 and 2 and their receptors were identified, linked to Tollip, Ran, PSMA1, and PSMA4. By contrast for T-6h-treated EVs, a unique pathway is found centered on the guanine nucleotide-binding protein family. After MaxQuant followed by Perseus analyses on the triplicate experiments conducted with a p value 1%, a heatmap has been constructed ([Figure S3](#mmc1){ref-type="supplementary-material"}). From the Heatmap, good separation can be observed between the isolated EVs and the secretome (proteins that passed the Amicon filter, EV). Two branches separating the EVs treated (T-6h) or non-treated (T-0h) are observable ([Figure S3](#mmc1){ref-type="supplementary-material"}). One of the two branches separates the secretome proteins from the EVs T-6h proteins. The secretome proteins is then separated by two sub-branches between T-0h and T-6h. However, some T-0h EVs proteins are masked by the T-0h secretome proteins but can be separated from them in subsidiary branches. This indicates that trypsin digestion is necessary to better separate the EVs from the rest of the cellular secreted factors ([Data S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, [S3](#mmc4){ref-type="supplementary-material"}, and [S4](#mmc5){ref-type="supplementary-material"}). We then decided to separate the EVs proteins that are at the membrane and the ones that are extracellular to those that are inside. ANOVA tests were performed with non-supervised clustering of samples ([Figure 3](#fig3){ref-type="fig"}A). Three clear clusters were highlighted. The first is vertical separating samples between membrane proteins and internal proteins; the second and the third clusters are horizontal describing proteins groups. Cluster 1 regroups 29 proteins, Cluster 2 groups 17 proteins, and Cluster 3 groups only eight proteins ([Table 1](#tbl1){ref-type="table"}). Based on the identified proteins in the different samples, schemes of EVs protein contents treated or non-treated have been drawn ([Figure 4](#fig4){ref-type="fig"}). Enrichment analyses of each of these three clusters showed that cluster 1 corresponds to proteins involved in cell proliferation, growth, differentiation, adhesion, migration, and apoptosis ([Figure 4](#fig4){ref-type="fig"}). Cluster 2 corresponds to proteins involved in cell transformation, tumor microenvironment, and cancer. Cluster 3 regroups proteins involved in cell migration, internalization, proliferation, and tumor microenvironment in the C6 glioma ([Figure 3](#fig3){ref-type="fig"}B and [Data S5](#mmc6){ref-type="supplementary-material"}, [S6](#mmc7){ref-type="supplementary-material"}, and [S7](#mmc8){ref-type="supplementary-material"}). Comparison between clusters suggests a strong pro-tumoral potential of C6 glioma EVs ([Figure S2](#mmc1){ref-type="supplementary-material"} and [Data S5](#mmc6){ref-type="supplementary-material"}, [S6](#mmc7){ref-type="supplementary-material"}, and [S7](#mmc8){ref-type="supplementary-material"}). Pre-treated and non-pre-treated EVs revealed that the pre-clearance of extravesicular proteins enhanced our ability to identify a broader range of EVs-specific protein species. As a matter of example, we identified a variation of expression of the EVs surface proteins CD9, CD63, Mac2 BP, lactadherin, poly-ubiquitin b, neurensin, Celsr1, and Denn5b in non-treated EVs, whereas in treated EVs, we detected CD81, CD82,Ust, Vcan, Lamp 1, rab43, Cspg4, Annexin A2, Synthenin 1, and VSP37b. Similarly, Actbl2, P-deshydrogenase, Acan, albumin, osteopotin, Sec14-like2, and pdcd6ip are found only at T-6h ([Figure 4](#fig4){ref-type="fig"}). These results establish evolution of surface protein nature in EVs produced by glioma cells over time.Figure 3Proteomic Analyses of rat Glioma C6 EVs(A) Heatmap of the FASP sample obtained according to the different steps described in [Figure 2](#fig2){ref-type="fig"}; external samples are the first elution representing the membrane digested protein at 6 h and some free proteins, internal samples are the proteins extracted from the EVs (top part of the Amicon).(B) Systemic biology analyses. The pathways from systemic biology analyses of clusters 1, 2, and 3 from the heatmap.Table 1Clusters of Specific Proteins Identified in the Internal Part of Glioma C6 EVs in the Time Course of Trypsin/Lys C Digestion after Permutation-Based FDR 0.01Cluster 1Cluster 2Cluster 3H2afj; H2afzH2afj; H2afzFn1PcolceLgals3bpUba52; Rps27a; Ubb; UbcLgals3bpFn1Itgb1Fn1Uba52; Rps27a; Ubb; UbcHspa8Spp1Lamp1Mfge8Rab7aCd63Anxa2Uba52; Rps27a; Ubb; UbcCd9VcanNcam1Itgb1Pdcd6ipLamp1Hist1h4bCd63Hspa8Cd9Mfge8Itgb1Ltbp1Hist1h4bAnxa2Rap1a; Rap1bVcanHspa8SdcbpMfge8Pdcd6ipLtbp1Htra1Anxa2Tmem55aEcm1Pttg1ipPlscr3VcanSdcbpNotch2Pdcd6ipHtra1Flot1Flot2Figure 4Proteins of Glioma EVsSchema of proteins identified from C6 glioma EVs non-treated (T-0h) and treated 6h with Trypsin/Lys C (T-6h).

Ghost Protein Identification {#sec2.3}
----------------------------

The internal fraction of proteomic analysis shows some AltProts in the internal part of the EVs. In total six AltProts are identified with minimum one unique peptide ([Table 2](#tbl2){ref-type="table"}), showing different expression after trypsin digestion ([Table 3](#tbl3){ref-type="table"}). IP_2634467 (AltOdf3l1) is identified in both conditions, treated and non-treated EVs; other AltProts like IP_2656216 (AltKlhl29) are recovered only after a 6 h digestion. Finally, the majority of AltProts are identified at 0 h, e.g., IP_2659453, an AltProt formed from an ncRNA (LOC103695286) specifically identified in MS/MS. This AltProt has some homology with the predicted, but not observed, protein rCG63645. This homology can drive the structure and function prediction of this AltProt. IP_2613134 (AltOtud7b), IP_2683599 (AltThoc7), and IP_2577320 (AltMilr1) are specifically identified in non-treated EVs. This suggests that some AltProts might be secreted directly in the media, whereas others are secreted into EVs.Table 2Description of the AltProt Identified in the EVsAltProt AccessionGeneTranscript AccessionUnique PeptidePSMProtein SequenceDNA SequenceTypeCoverage%IP_2656216Klhl29[XM_008764550.2](ncbi-n:XM_008764550.2){#intref0025},[XM_017594070.1](ncbi-n:XM_017594070.1){#intref0030}12MGQAVWRCVSWTC\
SYHSCVTMTCRR[LELSLENR]{.ul}VATGGGACAAGCTG\
TATGGAGATGTGTGAG\
CTGGACTTGTTCTTAC\
CATTCCTGTGTCACGA\
TGACATGCCGAAGGC\
TGGAGCTGTCCCTAG\
AGAACAGGGTGTGA5′UTR24IP_2659453LOC103695286[XR_001838245.1](ncbi-n:XR_001838245.1){#intref0035}11[MFCFCFVLFCFFLELR]{.ul}T\
EPRALCLLGKRSTTELPPIRDFATGTTTTGTTTTTGTT\
TTGTTTTGTTTTGTT\
TTTTTCTGGAGCTGAGG\
ACCGAACCCAGGGCTTT\
GTGCTTGCTAGGCAAGCG\
CTCTACCACTGAACTACC\
CCCGATTAGGGACTTTTAAncRNA41IP_2613134Otud7b[XM_006232957.3](ncbi-n:XM_006232957.3){#intref0040}12MIKPLTSVLTIPSIFSVPT\
PQDTKEQKEALRRKV\
VERRKVLISLHTLFQKTLR\
CVVGWWWSAAFRTS\
TIR[LLGLLASK]{.ul}YIPVCSRLCSCATGATCAAACCACTTA\
CCTCCGTTCTGACCATT\
CCCTCTATATTCTCCGT\
TCCCACACCTCAAGAC\
ACTAAAGAACAGAAGG\
AGGCTCTTAGAAGAAA\
AGTAGTGGAGAGAAGA\
AAAGTACTAATTTCCTTA\
CATACTTTATTCCAGAAG\
ACACTGAGGTGTGTGG\
TGGGGTGGTGGTGGTC\
AGCAGCCTTTAGGACTT\
CTACAATCAGGCTTCTA\
GGCCTGCTTGCTAGCAA\
GTACATACCTGTTTGTTCC\
AGACTCTGCTCATGCTAG3′UTR9IP_2634467Odf3l1[XM_008766272.2](ncbi-n:XM_008766272.2){#intref0045},[XM_017595650.1](ncbi-n:XM_017595650.1){#intref0050}15MTTDRGWGLKLCR[LLLQQDSR]{.ul}\
RGHSQAPSPPPGSKEVPVGSATGACCACAGACAGAGG\
ATGGGGTTTGAAGTTGTG\
CAGGCTTCTGCTCCAGC\
AGGACTCAAGGAGGGG\
CCATTCCCAGGCCCCCT\
CCCCACCCCCAGGCTC\
TAAGGAAGTGCCT\
GTGGGATCCTGA5′UTR20IP_2683599Thoc7[XM_017599648.1](ncbi-n:XM_017599648.1){#intref0055}11MIIKRSLKIFSRTLVWWY\
LVPCCFLLHLCLTSHM\
GCK[LSDLGAESR]{.ul}TW\
VLRKSRMHSATGATCATAAAGCGAA\
GTTTAAAGATTTTTAGT\
CGCACATTGGTGTGG\
TGGTATTTAGTCCCTTGC\
TGTTTCCTACTGCATTT\
ATGTTTGACATCCCACAT\
GGGCTGTAAACTCTCAGA\
CTTGGGTGCTGAGAGCC\
GAACTTGGGTCCTCAGG\
AAGAGCAGAATGCATTCTTAA5′UTR16IP_2577320Milr1[XM_017597497.1](ncbi-n:XM_017597497.1){#intref0060},[XM_008768388.2](ncbi-n:XM_008768388.2){#intref0065}11[MCMGQHMPR]{.ul}YVHA\
GRRTSWGSQLSPYS\
MRPWHRTKVIKFGG\
QHGWTPSQHTATGTGCATGGGCCAAC\
ATATGCCAAGGTATG\
TGCACGCAGGTCGGAGG\
ACGAGTTGGGGGAGTCA\
GCTTTCTCCTTACTCCA\
TGAGACCCTGGCATAGA\
ACTAAGGTCATCAAGTTT\
GGTGGCCAGCACGGTTGG\
ACCCCGAGCCAACACACCTGA3′UTR18[^4]Table 3Repartition of AltProts Identification on the Samples ConditionAltProt AccessionInternal EVs 0 hExternal Membrane 0 hInternal EVs 6 hExternal Membrane 6 hIP_26562160020IP_26594531000IP_26131342000IP_26344673020IP_26835991000IP_25773201000[^5]

Discussion {#sec3}
==========

Taken together, our results confirm that C6 glioma EVs carry a majority of proteins that are involved in tumor transformation and proliferation. Specific proteins identified in EVs are involved in tumor progression and bad prognosis. For example, Mac-2 BP binds with galectin-1, galectin-3, and galectin-7 and is associated with shorter survival, occurrence of metastasis, and/or a reduced response to chemotherapy in patients with different types of malignancy ([@bib7]). Similarly, Notch1, Notch2, and osteopontin are also bad prognostic factors in glioma ([@bib25], [@bib29]).

We also identified Dennd5b. Dennd5b and Dennd5a are markers of glioma according to the Brain Atlas (<https://www.proteinatlas.org/>). This protein family is also known to be epileptic marker ([@bib8]). These results can explain why some patients present epileptic behavior linked to glioma development. Finally, we detected six AltProts in glioma EVs. One corresponds to a non-coding RNA. The other five have their RNA also coding for reference proteins known to be involved in glioma: Kelch like family member 29 (Klhl29), OTU domain-containing protein 7B (Otud7b) known to act as a negative regulator of the B-cell response, outer dense fiber protein 3-like protein 1 (Odf3l1) marker of glioma hypoxia, THO complex subunit 7 homolog (Thoc7), and Milr1 (allergin-1), which plays an inhibitory role in the degranulation of mast cells. Taken together, we demonstrate and describe for the first time the presence of AltProts, which can be specific biomarkers and may be useful to target glioma EVs in body fluids for diagnosis.

Limitations of the Study {#sec4}
========================

In agreement with the fact that the AltProts are not referenced, it is complicated at present to monitor and quantify the AltProts by classical approach such as the western blot based on the use of antibodies. The MS strategy remains the best method for identifying this type of protein. The expression of RNA transcripts can also provide information on the expression capacity of these proteins, although the presence of an RNA does not guarantee the production of the protein. The MS strategy uses AltProt prediction; if the databases are getting richer and safer, certain models like the RAT still present a not well-annotated genome. Thus the AltProt database based on Rnor_6.0 genomic data needs to evolve. Finally, if we demonstrate the presence of AltProt in variable amounts under different conditions, their present function remains. Studies of the AltProt interactome have previously been undertaken ([@bib2], [@bib3]) and have given some clues and showed that they may be involved in phenotypic changes, and in the signaling pathways of gene expression ([@bib4]).

Methods {#sec5}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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